Pancreatic Ductal Adenocarcinoma and Immune Checkpoint Inhibitors: The Gray Curtain of Immunotherapy and Spikes of Lights

Pancreatic Ductal Adenocarcinoma and Immune Checkpoint Inhibitors: The Gray Curtain of Immunotherapy and Spikes of Lights

Pancreatic ductal adenocarcinoma (PDAC) is a dismal disease with a poor 5-year overall survival rate (~10%). The revolution of immunotherapy in clinical oncology has not substantially changed clinical outcome for patients with PDAC. Despite outstanding efforts, neither immune checkpoint inhibitors (...

Full description

Bibliographic Details
Main Authors: Rita Balsano, Valentina Zanuso, Angelo Pirozzi, Lorenza Rimassa, Silvia Bozzarelli
Format: Article
Language:English
Published: MDPI AG 2023-03-01
Series:Current Oncology
Subjects:
PDAC
immunotherapy
ICIs
PD-1
PD-L1
CTLA-4
Online Access:https://www.mdpi.com/1718-7729/30/4/293

Internet

https://www.mdpi.com/1718-7729/30/4/293

Similar Items